Fab’entech news

Fabentech, a pharmaceutical-stage biotechnology company specialized in the development, production and marketing of polyclonal antibodies for responding to emergency situations and treating emerging infectious diseases, today announced that it has been chosen to be a part of the COUNTERACT European consortium that is aiming to develop medical countermeasures to cope with CBRN threats.

“Within an unstable public health and geopolitical context, the CBRN risk has become a cruc

The EPIC-CROWN-2 project, initiated by the Lyon-based biotech company, has received funding to the tune of 9.2 million euros from the European Commission. Thanks to this grant, awarded in the context of the first call for HERA projects (HERA is a new European authority dedicated to preparing and responding to health emergencies), Fab’entech will be able to accelerate the development of its clinical programme in order to provide, as rapidly as possible, its treatment against SARS-C

Fab`entech, a French biotech specialised in the development and production of polyclonal antibodies, presents its new industrial site located in Saint-Priest, to the south-east of Lyon. The 1,000 m2 production site is now operational and will give Fab`entech the capacity to manufacture all of its innovations (biodefense and anti-COVID-19 programme: FabenCOV) in France. Close-up of this new site, a key asset in the development of the biotech`s activities.

A cutting

Fab’entech, a Lyon-based biopharmaceutical company specialised in immunotherapies for emergency situations, is today announcing the launch of a programme to develop an immunotherapy treatment against COVID-19. The treatment will be indicated in severely ill patients requiring respiratory assistance. The clinical trials are expected to begin in humans in 2021.

In order to meet the new public health challenges, Fab’entech has built a development and production platform based

Fab’entech, a Lyon-based biopharmaceutical company created in 2009 and specialised in immunotherapy for emergency situations, completes a new round of fundraising of 8.5 million euros led by Definvest, the fund of the Armed forces ministry managed by Bpifrance, with the participation of the Institut Mérieux and of its historical investors, Elaia, Sigma Gestion and Kreaxi – private investors – and its founder, Bertrand Lépine.

With these raised funds, Fa